Sellas says galinpepimut-S cut death risk 41% in Phase 3 AML trial
Sellas Life Sciences said on Tuesday that its experimental immunotherapy galinpepimut-S reduced the risk of death by 41% compared with standard treatment in patients with an...
AI and the frontier tech around it, explained every morning
Stories about Phase 3 trial · 3 stories
Sellas Life Sciences said on Tuesday that its experimental immunotherapy galinpepimut-S reduced the risk of death by 41% compared with standard treatment in patients with an...
Helus Pharma said Monday that its psychedelic drug candidate HLP003 significantly reduced depression scores in a Phase 3 trial, but the study also recorded a number...
CG Oncology said Monday that cretostimogene, an immunotherapy infused directly into the bladder…